SequelSEC

SUPERNUS PHARMACEUTICALS, INC. SUPN

Pharmaceutical Preparations · CIK 0001356576 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$830.44M
Fiscal year ended 2026-06-30
Operating income
-$130.46M
Fiscal year ended 2026-06-30
Free cash flow
$18.79M
Fiscal year ended 2026-06-30

SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $830.44M and net income of -$109.89M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from SUPERNUS PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SUPERNUS PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$830.44M
Cost of revenue$99.03M
Gross profit$731.41M
Operating income-$130.46M
Net income-$109.89M
Research & development$126.09M
Weighted-average diluted sharesUnavailable
Pretax income-$123.47M
Income tax expense-$13.58M
Diluted EPSUnavailable
Selling, general & administrative$560.88M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

SUPERNUS PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$179.95M
Total assets$1.43B
Current assets$723.50M
Total liabilities$396.88M
Current liabilities$347.38M
Total equity incl. NCI$1.03B
Temporary (mezzanine) equityUnavailable
Inventory$107.03M
Accounts receivable$211.66M
Goodwill$119.43M
Long-term debtUnavailable
Accounts payable$5.59M

Cash flow

SUPERNUS PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$19.91M
Capital expenditures$1.12M
Investing cash flow-$14.73M
Financing cash flow$31.51M
Net change in cash$36.69M
Stock-based compensation$34.60M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$27.53M

Derived

SUPERNUS PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$18.79M
Gross margin88.1%
Operating margin-15.7%
FCF margin2.3%
SBC / revenue4.2%
Current ratio2.08x
Revenue YoY growth24.9%
Net margin-13.2%
R&D / revenue15.2%
CapEx / revenue0.1%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SUPN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.